Quotient (DB:U4W0) - Prezzo delle azioni, notizie e analisi

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

U4W0 Panoramica delle azioni

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. Maggiori dettagli

U4W0 analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	0/6
Dividendi	0/6

Analisi del rischio

Non ha una capitalizzazione di mercato significativa ( €3M )

Ha meno di 1 anno di pista di cassa

Patrimonio netto negativo

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

+ 2 più rischi

Quotient Limited Concorrenti

Bioservo Technologies

MUN:10B

€4.3m

elexxion

XTRA:E8X

€3.0m

MagForce

XTRA:MF6

€3.6m

aap Implantate

XTRA:AAQ1

€22.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Quotient
Prezzi storici delle azioni
Prezzo attuale dell'azione	€0.12
Massimo di 52 settimane	€15.36
Minimo di 52 settimane	€0.018
Beta	1.36
1Variazione di 1 mese	313.79%
Variazione a 3 mesi	196.30%
Variazione di 1 anno	-99.22%
3Variazione a 3 anni	-99.96%
Variazione a 5 anni	-99.96%
Variazione dall'IPO	-99.92%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	U4W0	DE Medical Equipment	DE Mercato
7D	0%	-4.9%	-1.5%
1Y	-99.2%	-5.6%	7.9%

Ritorno vs Industria: U4W0 ha avuto una performance inferiore rispetto al German Medical Equipment che ha registrato un rendimento -5.6 % nell'ultimo anno.

Rendimento vs Mercato: U4W0 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 7.9 % nell'ultimo anno.

Volatilità dei prezzi

Is U4W0's price volatile compared to industry and market?
U4W0 volatility
U4W0 Average Weekly Movement	95.4%
Medical Equipment Industry Average Movement	5.8%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di U4W0 è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di U4W0 è aumentata da 63% a 95% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2007	432	Manuel Mendez	www.quotientbd.com

Quotient Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Quotient con la sua capitalizzazione di mercato?
U4W0 statistiche fondamentali
Capitalizzazione di mercato	€2.53m
Guadagni(TTM)	-€112.90m
Ricavi(TTM)	€34.05m

0.1x

Rapporto P/S

0.0x

Rapporto P/E

U4W0 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
U4W0 Conto economico (TTM)
Ricavi	US$37.41m
Costo del fatturato	US$37.13m
Profitto lordo	US$279.00k
Altre spese	US$124.31m
Guadagni	-US$124.03m

Ultimi guadagni dichiarati

Dec 31, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)	-5.89
Margine lordo	0.75%
Margine di profitto netto	-331.54%
Rapporto debito/patrimonio netto	-126.2%

Come si è comportato U4W0 nel lungo periodo?

Vedi performance storica e confronto

This company listing is no longer active

U4W0 Panoramica delle azioni

Analisi del rischio

Quotient Limited Concorrenti

MUN:10B

€4.3m

XTRA:E8X

€3.0m

XTRA:MF6

€3.6m

XTRA:AAQ1

€22.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Quotient Limited Appoints James Harman Gaudin to its Board of Directors

Quotient Limited Filed for Bankruptcy

Quotient Limited(OTCPK:QTNT.F) dropped from NASDAQ Composite Index

Quotient Limited Announces Resignation of Franz Walt as Director

Quotient Announces Intent to Voluntary Delist from the Nasdaq Global Market

High number of new directors

Recent updates

Quotient Limited Appoints James Harman Gaudin to its Board of Directors

Quotient Limited Filed for Bankruptcy

Quotient Limited(OTCPK:QTNT.F) dropped from NASDAQ Composite Index

Quotient Limited Announces Resignation of Franz Walt as Director

Quotient Announces Intent to Voluntary Delist from the Nasdaq Global Market

High number of new directors

Quotient Limited Announces the Retirement of Brian McDonough as Member of the Board of Directors

High number of new directors

High number of new directors

Independent Chairman of the Board recently bought €140k worth of stock

Quotient Limited Appoints Sophie Bechu as A Director

Quotient Receives Non-Compliance Letter from Nasdaq

First quarter 2023 earnings released: US$0.37 loss per share (vs US$0.27 loss in 1Q 2022)

Quotient Limited Provides Earnings Guidance for the Fiscal Year Ending March 31, 2023

Quotient Limited to Report Q1, 2023 Results on Aug 09, 2022

Quotient Limited, Annual General Meeting, Oct 31, 2022

Quotient Limited Announces Executive Changes

Quotient Limited Provides Earnings Guidance for the Fiscal Year 2023

Full year 2022 earnings released: US$1.23 loss per share (vs US$1.18 loss in FY 2021)

Quotient Limited to Report Q4, 2022 Results on Jun 22, 2022

Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics

Quotient Receives Non-Compliance Letter from Nasdaq

Quotient Receives Non-Compliance Letter from Nasdaq

Quotient Limited Appoints Thomas Aebischer to Quotient Board of Directors, Effective as of May 1, 2022

Quotient Limited Appoints Manuel O. Méndez as Director

Quotient Limited Appoints Thomas Aebischer to Board of Directors, Effective as of May 1, 2022

Independent Chairman of the Board recently bought €70k worth of stock

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Quotient Limited to Report Q3, 2022 Results on Feb 08, 2022

Chief Commercial Officer recently bought €91k worth of stock

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.16 loss in 2Q 2021)

Chief Commercial Officer Jeremy Stackawitz has left the company

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.32 loss in 1Q 2021)

Full year 2021 earnings released: US$1.18 loss per share (vs US$1.44 loss in FY 2020)

Quotient Limited Provides Revenue Guidance for the First Quarter and Full Year Ending March 31, 2022

Quotient Limited announced that it has received $95 million in funding from Highbridge Capital Management, LLC, CI Global Asset Management, Russell Investments Canada Ltd., Whitebox Advisors, LLC

Quotient Limited announced that it expects to receive $95 million in funding from Highbridge Capital Management, LLC and other investors

New 90-day low: €3.90

Quotient Limited Announces Manuel Mendez as Chief Executive Officer, Effective April 1, 2021

Chief Commercial Officer recently sold €129k worth of stock

New 90-day low: €4.06

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.37 loss in 3Q 2020)

Revenue beats expectations

Quotient Limited to Report Q3, 2021 Results on Feb 01, 2021

Quotient Limited Announces Resignation of Ed Farrell from His Position as Chief Operating Officer

Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for the US Market

New 90-day high: €5.30

Second quarter 2021 earnings released: US$0.18 loss per share

Revenue beats expectations

Quotient Limited to Report Q2, 2021 Results on Nov 02, 2020

Quotient Limited Receives Receipt of U.S. FDA Emergency Use Authorization or Mosaiq COVID19 Antibody Test

Quotient Limited has completed a Follow-on Equity Offering in the amount of $75.000001 million.

New 90-day low - €4.54

New 90-day low - €5.60

Earnings released

Quotient Limited to Report Q1, 2021 Results on Aug 03, 2020

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda